# Gilead Sciences, Inc.  Share Price Target ‘$78.46’, now 12.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc.share-price-target-78.46-now-12.8-upside-potential/4121150569
- Published: 2024-04-05T14:02:28+01:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** with ticker code (GILD) now have 25 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘buy’. The target price
High/Low ranges between $111.64 and $63.66 calculating the mean target share price
we have $78.46. (at the time of writing). Now with the previous closing price of
$69.55 this indicates there is a potential upside of 12.8%. There is a 50 day moving
average of $74.22 and the 200 day MA is $77.09. The company has a market capitalization
of 86.08B. The stock price for the company is currently $69.04 USD

 The potential market cap would be $97,112,807,659 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 15.34, revenue per share of $21.73
and a 9.78% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on: